Screener
Pasithea Therapeutics KTTA Q1 2026 earnings
Reported May 15, 2026 · After market close
EPS-$0.12Beat by $0.33
Revenue estimate$100.0K
EPS estimate-$0.45
Next report
Date not yet announcedVersus estimates
Diluted EPS
Q2 2026-$0.16In line
Q1 2026-$0.12Beat by $0.33
Q4 2025-$0.89Miss by $0.71Q4 2026-$0.18In lineQ3 2025-$0.41Q2 2025-$0.66FAQ
- When did Pasithea Therapeutics report Q1 2026 earnings?
- Pasithea Therapeutics (KTTA) reported Q1 2026 earnings on May 15, 2026 after market close.
- What were Pasithea Therapeutics's Q1 2026 revenue and EPS?
- Pasithea Therapeutics reported eps of $-0.12 for Q1 2026.
- Did Pasithea Therapeutics beat estimates in Q1 2026?
- EPS beat the consensus estimate of $-0.45 by $0.33.
- How did Pasithea Therapeutics's Q1 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 92.5% from $-1.61.
- Where can I find Pasithea Therapeutics's Q1 2026 SEC filings?
- You can read the 10-Q periodic report (0001213900-26-057837) directly on SEC EDGAR. The filing index links above go to sec.gov.
